

Ref: BHL/STEX 6/ 2026-27

Date: May 08, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051
Scrip Code: 539872	Symbol: BAJAJHCARE

Sub: Outcome of the Board Meeting held on May 08, 2026

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") we hereby inform you that the Board of Directors of our Company at its meeting held today i.e. May 08, 2026, has considered and approved the following:

1. The Audited Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2026 along with the Auditor's Report thereon.

The Audited Standalone Financial Results for the quarter and financial year ended March 31, 2026 along with the Auditors' Report issued by Walker Chandok & Co LLP, Chartered Accountants, Statutory Auditors of the Company in accordance with the Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 is attached herewith as '**Annexure A**'.

The declaration that the Report of Statutory Auditors is with unmodified opinion with respect to Audited Standalone Financial Results for the financial year ended March 31, 2026 is attached herewith as '**Annexure B**'.

2. Recommended a Final Dividend at the rate of 30% of the Face Value of Rs. 5/- each i.e. Rs. 1.50/- per equity share of the Company for the financial year 2025-26, subject to the approval of Shareholders of the Company at the ensuing Annual General Meeting of the Company.
3. Appointment of M/s. JCR & Co. LLP, Chartered Accountants, as Internal Auditors of the Company for the financial year 2026-27.
4. Re-appointment of M/s. V.J. Talati & Co., Cost Accountants, as Cost Auditors of the Company for the financial year 2026-27.

The details required under Regulation 30 of Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are given in '**Annexure C**'.

We wish to inform you that the Board Meeting commenced today at 5.15 p.m. and concluded at 6.30 p.m.

Kindly take the same on record.

Thanking you.
Yours faithfully,

For and on behalf of Bajaj Healthcare Limited

MONICA Digitally signed by
MONICA TANWAR
TANWAR Date: 2026.05.08
20:18:46 +05'30'

Monica Tanwar
Company Secretary & Compliance Officer
Encl: as above

BAJAJ HEALTHCARE LIMITED

(CIN No.: L99999MH1993PLC072892)

(Reg. and Corp. Office: 6th Floor, Bhoomi Velocity Infotech Park, Above ICICI Bank, Road No. 23, Wagle Industrial Estate, Thane (W) - 400 604)
(Tel: + 91-22-6617400, Email: investors@bajajhealth.com, Website: www.bajajhealth.com)

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31 MARCH 2026

(Rs. In Lakhs except for Earnings Per Share)

Particulars	Quarter Ended			Year Ended	
	31 March 2026	31 Dec 2025	31 March 2025	31 March 2026	31 March 2025
	(Refer Note 2)	(Unaudited)	(Refer Note 2)	(Audited)	(Audited)
A. Continuing Operations					
I. Revenue from operations	15,305.75	16,122.27	15,447.25	61,103.14	54,260.24
II. Other Income	295.62	164.71	1,357.16	713.39	1,940.44
III. Total Income (I+II)	15,601.37	16,286.98	16,804.41	61,816.53	56,200.68
IV. Expenses					
(a) Cost of materials consumed	9,210.06	6,940.90	10,049.09	30,619.95	30,710.90
(b) Changes in Inventories of Finished Good and Work-in-progress	(1,059.01)	1,128.63	(652.23)	1,019.54	(2,066.37)
(c) Employee benefits expense	1,630.11	1,558.66	1,570.60	6,275.26	5,705.83
(d) Finance Costs	556.58	588.35	607.58	2,223.37	2,790.44
(e) Depreciation and amortisation expense	782.87	720.11	753.10	2,754.84	2,791.78
(f) Other expenses	3,256.98	3,425.87	3,304.07	12,706.61	11,667.33
Total Expenses	14,357.59	14,362.52	15,632.21	55,599.57	51,599.91
V. Profit before Exceptional Items and Tax Expense	1,243.78	1,924.46	1,172.20	6,216.96	4,600.77
VI. Exceptional items (Refer Note 7)	(3,324.66)	-	-	(3,324.66)	-
VII. Profit / (Loss) Before Tax	(2,080.88)	1,924.46	1,172.20	2,892.30	4,600.77
VIII. Tax Expense					
(a) Current tax	-	-	-	-	-
(b) Deferred Tax	(139.60)	314.37	12.90	761.26	307.89
Total Tax Expenses	(139.60)	314.37	12.90	761.26	307.89
IX. Profit / (Loss) after Tax from Continuing Operations	(1,941.28)	1,610.09	1,159.30	2,131.04	4,292.88
B. Discontinued Operations					
X. Loss before Tax from Discontinued Operations (Refer note 4)	(230.18)	(57.08)	(88.03)	(511.69)	(401.11)
XI. Tax Impact of Discontinued Operations	113.60	(14.37)	(46.51)	42.74	(57.78)
XII. Loss after Tax from Discontinued Operations	(343.78)	(42.71)	(41.52)	(554.43)	(343.33)
XIII. Profit / (Loss) for the period / year (IX + XII)	(2,285.06)	1,567.38	1,117.78	1,576.61	3,949.55
XIV. Other comprehensive Income					
Continuing Operations					
(i) Items that will not be reclassified to profit or loss					
- Remeasurement of Post Employment Benefit Obligations	6.49	25.00	461.27	81.49	183.09
(ii) Income tax relating to items that will not be reclassified to profit or loss	(1.63)	(6.29)	(116.10)	(20.51)	(46.08)
Total Other Comprehensive Income from Continuing Operations	4.86	18.71	345.17	60.98	137.01
Discontinued Operations					
(i) Items that will not be reclassified to profit or loss	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
Total Other Comprehensive Income from Discontinued Operations	-	-	-	-	-
Other Comprehensive Income for the Period / Year	4.86	18.71	345.17	60.98	137.01
XV. Total Comprehensive Income for the Period / Year (XIII + XIV)	(2,280.20)	1,586.09	1,462.95	1,637.59	4,086.56
XVI. Paid-up Equity Share Capital (Face Value Rs. 5 per share)	1,683.13	1,579.16	1,579.16	1,683.13	1,579.16
XVII. Other Equity				51,617.10	45,037.26
XVIII. EPS (Not Annualised except for the year ended 31 March 2025 and 31 March 2026)					
Continuing Operations					
(a) Basic EPS (in Rs.)	(6.08)	5.10	3.67	6.73	14.45
(b) Diluted EPS (in Rs.)	(6.07)	5.01	3.59	6.72	14.26
Discontinued Operations					
(a) Basic EPS (in Rs.)	(1.08)	(0.14)	(0.13)	(1.75)	(1.16)
(b) Diluted EPS (in Rs.)	(1.08)	(0.14)	(0.13)	(1.75)	(1.14)
Total Operations					
(a) Basic EPS (in Rs.)	(7.16)	4.96	3.54	4.98	13.29
(b) Diluted EPS (in Rs.)	(7.15)	4.87	3.46	4.97	13.12



Notes :

- The above Financial Results of Bajaj Healthcare Limited (the 'Company') have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 08 May 2026. These results have been subjected to limited review by the Statutory auditors who have expressed an unmodified review conclusion.
- The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year.
- The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals.
- In the year ended 31 March 2024, the Board of Directors had approved to sale/disposal of undertaking/unit(s) on going concern basis, situated at plot no. N-92, L-9/3, T-30, MIDC Tarapur, Taluka- Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D-2/CH/42 & D-2/CH/43 Dahej industrial area, GIDC, Bharuch, Gujarat (which were acquired under SARFAESI ACT, 2022 from Saraswat Bank) and plot no.E-62 and E-63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale/disposal under Ind AS 105 ("Non-current Assets Held for Sale and Discontinued Operations"). The results of the operation of these units have been presented separately on the Statement of Profit and Loss as Discontinued Operations. Out of these, one unit situated at plot no. N-92 was sold during the Quarter ended 31 March 2024 and one unit situated at plot no. L-9/3 was sold during the Quarter ended 31 March 2026. The total value of assets classified as held for sale represents lower of carrying value or fair value.

The financial information from discontinued operations:

Particulars	Quarter Ended			Year Ended	Year ended
	31 March 2026	31 Dec 2025	31 March 2025	31 March 2026	31 March 2025
	(Refer Note 2)	(Unaudited)	(Refer Note 2)	(Audited)	(Audited)
Total Income (A)					
Total Expenses (B)	10.61	(1.05)	(37.81)	11.71	58.07
Loss before Tax from Discontinued Operations (C = A - B)	240.79	56.03	50.22	523.40	459.18
Tax Credit from Discontinued Operations (D)	(230.18)	(57.08)	(88.03)	(511.69)	(401.11)
Loss after Tax from Discontinued Operations (E = C - D)	113.60	(14.37)	(46.51)	42.74	(57.78)
	(343.78)	(42.71)	(41.52)	(554.43)	(343.33)

- The Board of Directors at its meeting held on 18 March 2026, considered and approved the allotment of 20,79,409 fully Paid-up Equity Shares of the Company of face value of Rs. 5 each ("the Equity Shares") to the Promoter, Promoter Group and Person(s) belonging to the Non-Promoter Public Category, pursuant to the exercise of the option for Conversion of Warrants into Equity Shares at a price of Rs. 338 per Equity Share (including a premium of Rs. 333) for each Convertible Warrant. The allotment has been made pursuant to the Special Resolution passed by the shareholders at the Extra-Ordinary General Meeting held on 7 August 2024, in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Earlier, on 19 September 2024, the Company had allotted 39,84,852 equity shares and 20,79,409 convertible warrants, raising an aggregate amount of Rs. 15225.90 lakhs. This amount included 25% of the warrant issue price, aggregating to Rs.1,757.10 lakhs, which was received at the time of allotment of the convertible warrants. The balance 75% i.e Rs 5,271.30 lakhs of the issue price has now been received upon the allotment of 20,79,409 equity shares pursuant to the exercise of conversion rights attached to the warrants.

The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities.

Particulars	Amount to be Utilised	Utilised up to 31 March 2026	Unutilised Balance
Repayment of Loan	15,000.00	15,000.00	-
Investment in Capital Expenditure	3,500.00	315.90	3,184.10
General corporate purposes	1,997.00	1,984.28	12.72
Total	20,497.00	17,300.18	3,196.82

- The Company had entered into a Transfer of Technical Know-how arrangement with a customer for one of the products manufactured by the Company. The Technical know-how was ultimately to be used by a customer in Middle East. Due to on-going regional instability in Middle East, the customer was not able to meet its committed timeline. Hence, the Company has reversed the income recognised in earlier year amounting to Rs. 3,324.66 lakhs, in the quarter ended 31 March 2026.
- In April 2025, the Company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) ("Genrx"), on a going concern basis. Genrx is an existing company incorporated under the provisions of the Companies Act, 1956. The acquisition was made for a total consideration of Rs. 1,085 lakhs. Subsequently, on 3 June 2025, the Company filed an application with the Hon'ble National Company Law Tribunal ("NCLT"), Mumbai, seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern, which is pending with NCLT as on 31 March 2026. Hence, Genrx has not been considered a subsidiary for consolidation purpose, pending requisite approvals from the NCLT, as control, defined under Ind AS 110 Consolidated Financial Statements is not established.



Date : 8 May 2026
Place: Thane



For and on behalf of the Board
For Bajaj Healthcare Limited

Mr. Sajankumar R. Bajaj
DIN : 00225950
Chairman and Managing Director

BAJAJ HEALTHCARE LIMITED
(CIN No.: L99999MH1993PLC072892)

BALANCE SHEET AS AT 31 MARCH 2026

(Rs. in Lakhs)

Particulars	As at 31 Mar 2026 (Audited)	As at 31 Mar 2025 (Audited)
A ASSETS		
1 Non-current assets		
(a) Property Plant & Equipment	21,755.52	22,167.27
(b) Right of Use Assets	2,966.96	1,537.18
(c) Capital Work in Progress	794.14	344.85
(d) Other Intangible Assets	98.18	140.36
(e) Intangible Assets Under Development	-	-
(f) Financial Assets		
i) Investments	0.33	0.33
ii) Other Financial Assets	1,369.62	275.00
(g) Non current tax Assets (Net)	370.74	572.98
(h) Deferred tax Assets (Net)	1,065.01	1,889.52
Total Non Current Assets	28,420.50	26,927.49
2 Current assets		
(a) Inventories	21,600.96	16,188.77
(b) Financial Assets		
(i) Trade receivables	23,385.38	25,167.42
(ii) Cash and cash equivalents	3,723.54	260.38
(iii) Bank Balance other than (ii) above	75.19	406.18
(iv) Other Financial assets	522.67	3,343.18
(c) Other Current Assets	7,600.48	3,460.22
Total Current assets	56,908.22	48,826.15
Non Current assets classified as Held for sale	6,993.00	7,550.98
TOTAL ASSETS	92,321.72	83,304.62
B EQUITY AND LIABILITIES		
1 Equity		
(a) Share Capital	1,683.13	1,579.16
(b) Other Equity	51,617.10	45,037.26
Total Equity	53,300.23	46,616.42
2 Liabilities		
Non-Current Liabilities		
(a) Financial Liabilities		
i) Borrowings	4,756.57	6,466.50
ii) Lease Liabilities	298.83	25.40
(b) Provisions	717.85	498.10
Total Non-Current Liabilities	5,773.25	6,990.00
3 Current Liabilities		
(a) Financial Liabilities		
i) Borrowings	18,589.77	15,795.92
ii) Lease Liabilities	1,263.91	37.19
iii) Trade Payables		
Total outstanding dues of Micro, Medium and Small enterprises	654.12	844.01
Total outstanding dues of creditors other than Micro, Medium and Small enterprises	10,873.87	9,140.20
iv) Other Financial Liabilities	350.06	575.57
(b) Other Current Liabilities	122.11	707.41
(c) Provisions	102.40	126.33
Total Current Liabilities	31,956.24	27,226.63
Liabilities Associated with Assets held for sale	1,292.00	2,471.57
Total Liabilities	39,021.49	36,688.20
Total Equity and Liabilities	92,321.72	83,304.62



For and on behalf of the Board
For Bajaj Healthcare Limited

Mr. Sajankumar R. Bajaj
DIN : 00225950
Chairman and Managing Director

Date : 8 May 2026
Place: Thane

BAJAJ HEALTHCARE LIMITED
(CIN No.: L99999MH1993PLC072892)

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 MARCH 2026

(Rs. in Lakhs)

Particulars	As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit/(Loss) before tax	2,380.61	4,199.66
From Continuing operations	2,892.30	4,600.77
From Discontinued operations	(511.69)	(401.11)
Adjustments for:		
Depreciation and amortisation expense	2,754.84	2,791.78
Profit on sale of Property Plant & Equipment	(15.39)	-
Finance Cost	2,223.37	2,790.44
Interest on Fixed deposits	(31.18)	(50.59)
Interest Income on Security Deposit	-	(0.40)
Unrealised Foreign Exchange Gain (Net)	(651.41)	(385.62)
Exceptional item	3,324.66	-
Share Based Compensation Expenses	101.25	-
Liabilities not required written back	-	(578.38)
Allowance for expected credit loss	300.00	75.00
Operating Profit before Working Capital Changes	10,386.75	8,841.89
Adjustments for:		
(Increase)/Decrease in Non-Current and Current Assets	(2,394.40)	1,102.04
(Increase)/Decrease In Trade receivable	2,133.45	(6,832.80)
(Increase)/Decrease In Inventories	(5,412.19)	(1,784.95)
Increase in non-current and current liabilities	892.28	1,294.46
Cash generated from operations	5,605.89	2,620.64
Income Tax paid (net)	202.24	(458.59)
Net Cash flow from Operating activities (A)	5,808.13	2,162.05
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property Plant & Equipment (including capital work-in-progress, capital advances and other intangible assets)	(4,334.96)	(1,153.85)
Proceeds from sale of Property Plant & Equipment	289.46	11.00
Interest on Fixed deposits	31.18	50.59
Amount paid for investment in Genrx	(810.00)	-
Proceeds from Bank balances not considered as cash and cash equivalent	202.65	-
Increase in Bank balances not considered as cash and cash equivalent	(156.28)	(389.25)
Net Cash used in Investing activities (B)	(4,777.95)	(1,481.51)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of Equity Shares and Share Warrants (net of expenses)	5,260.80	14,969.75
Repayment of Long Term Borrowing	(3,066.59)	(1,891.31)
Proceeds from Long Term Borrowing	96.15	4,500.00
Repayment of Short Term Borrowing (Net)	2,992.78	(15,136.74)
Principal payment of lease liabilities	(310.96)	(8.19)
Interest payment of lease liabilities	(106.40)	(4.72)
Interest paid	(2,116.97)	(2,790.44)
Dividend Paid	(315.83)	(275.98)
Net Cash used in from financing activities (C)	2,432.98	(637.63)
Net increase in Cash & Cash Equivalents (A+B+C)	3,463.16	42.91
Cash and Cash equivalents at the beginning of the period	260.38	217.47
Cash and Cash equivalents at the end of the period	3,723.54	260.38



For and on behalf of the Board
For Bajaj Healthcare Limited

Mr. Sajankumar R. Bajaj
DIN : 00225950
Chairman and Managing Director

Date : 8 May 2026
Place: Thane

Walker Chandio & Co LLP
42nd Floor,
Building Commerz III,
International Business Park,
Oberoi Garden City,
Off Western Express Highway,
Goregaon (East),
Mumbai-400063
T +91 22 6626 2699

Independent Auditor's Report on Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Bajaj Healthcare Limited

Opinion

1. We have audited the accompanying annual financial results ('the Statement') of **Bajaj Healthcare Limited** ('the Company') for the year ended **31 March 2026**, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'), .
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations; and
 - (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the net profit after tax and other comprehensive income and other financial information of the Company for the year ended 31 March 2026

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Bhubaneswar, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Guwahati, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandio & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Responsibilities of Management and Those Charged with Governance for the Statement

4. This Statement has been prepared on the basis of the annual financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net loss and other comprehensive income and other financial information of the Company in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes adequate maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
5. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing, specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;
 - Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern;



Bajaj Healthcare Limited

Independent Auditor's Report on Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11. The Statement includes the financial results for the quarter ended 31 March 2026, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No.: 001076N/N500013



Yashwant M. Jain

Partner

Membership No. 118782

UDIN: 26118782CDIVGU1269

Place: Mumbai

Date: 08 May 2026



'Annexure B'

Date: May 08, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Scrip Code: 539872	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Symbol: BAJAJHCARE
---	--

Dear Sir/Madam,

Sub: Declaration with respect to unmodified opinion in the Report of Statutory Auditors on Audited Standalone Financial Results for the Financial Year ended March 31, 2026

Pursuant to Regulation 33(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we hereby declare that the Auditors' Report on Standalone Financial Results for the financial year ended March 31, 2026 issued by Walker Chandok & Co LLP, Chartered Accountants (Firm Registration No.: 001076N/N500013), Statutory Auditors of the Company is with unmodified opinion.

This is for your information & records.

Thanking you

Yours Faithfully

For Bajaj Healthcare Limited

Rohan Parekh
Chief Financial Officer

BAJAJ HEALTHCARE LIMITED

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, Road No. 23, Above/CICI Bank, Wagle Industrial Estate, Thane(W) - 400604

• Tel: +91 22 6617 7400 - 499 • Fax : +91 22 66177458 • Website : www.bajajhealth.com

CIN No.: L99999MH1993PLC072892

‘Annexure C’

The details required under Regulation 30 of Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026

Appointment of M/s. JCR & Co. LLP, Chartered Accountants, as Internal Auditors of the Company for the Financial Year 2026-27

Sr. No.	Requirement of Disclosure	Information pertaining to such Disclosure
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment as Internal Auditor
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment	Appointed as Internal Auditor of the Company for the Financial Year 2026-27 at the Board Meeting held on May 08, 2026, to conduct Internal Audit and issue periodic internal audit report as per the provisions of the Companies Act, 2013.
3.	Brief Profile (in case of Appointment)	M/s. JCR & Co. LLP (FRN:105270W/W100846) is a multidisciplinary Chartered Accountancy firm established in 1972, providing Audit, Taxation, Advisory and Compliance related services across various sectors. The firm is empaneled with reputed regulatory authorities including RBI, SEBI and C&AG, with a strong professional presence across India.

Re-appointment of M/s. V.J. Talati & Co., Cost Accountants, as Cost Auditors of the Company for the Financial Year 2026-27

Sr. No.	Requirement of Disclosure	Information pertaining to such Disclosure
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-Appointment as Cost Auditor
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment	Re-appointed as Cost Auditor of the Company for the Financial Year 2026-27 at the Board Meeting held on May 08, 2026, to issue Cost Audit Report as per the provisions of the Companies Act, 2013.
3.	Brief Profile	M/s. V. J. Talati & Co., Cost Accountants, Mumbai (Firm Regd. No. R00213) has experience and expertise in conducting Cost Audit over the years. The firm also provides Guidance for maintenance of Cost Accounting Records as prescribed under the Companies (Cost Records and Audit) Rules, 2014. Additionally, it offers certification services regarding the proper maintenance of cost records by companies.